发明名称 Method for targeting cells involved in sclerotic and/or fibrotic diseases
摘要 A compound includes a carrier molecule wherein the carrier molecule is linked to a further molecule, wherein the further molecule is at least one cyclic peptide in which the cyclic peptide portion thereof contains at least one sequence encoding a cell receptor recognizing peptide (RRP) and with the proviso that the compound is not a naturally occurring receptor agonist or antagonist. Preferably, the RRP is a receptor specific for Hepatic Stellate Cells (HSC) or a receptor that is up-regulated on HSC during disease. The RFP may be chosen from among a PDGF receptor, a collagen type VI receptor, cytokine receptor(s) such as TGBbeta, INFalpha and interleukinbeta. The cyclic portion of the peptide can contain at least one amino acid sequence RGD or KPT. The compounds can be used as an active targeting ingredient for manufacturing a pharmaceutical composition for therapy, prophylaxis or diagnosis of a disease chosen from fibrotic disease, sclerotic disease, and chronic or acute inflammatory processes including glomeruloscherosis, interstitial fibrosis, lung fibrosis, atherosclerosis, rheumatoid arthritis, Crohns disease, colitis ulcerosa, glomerulonephritis and sepsis, and particularly for targeting HSC. Pharmaceutical compositions contain the above-compound(s).
申请公布号 US7348313(B2) 申请公布日期 2008.03.25
申请号 US20040012056 申请日期 2004.12.15
申请人 STICHTING VOOR DE TECHNISCHE WETENSCHAPPEN;RIJKSUNIVERSITEIT GRONINGEN 发明人 POELSTRA KLAUS;BELJAARS ELEONORA;MEIJER DRIK KLAUS FOKKE;SCHUPPAN DETLEF BRUNO IGOR
分类号 A61K31/7004;G01N33/566;A61K9/00;A61K38/12;A61K47/42;A61K47/48;A61K51/08;A61P1/00;A61P7/00;A61P9/10;A61P11/00;A61P13/00;A61P19/02;A61P29/00;A61P43/00;C07K14/71;C07K14/715;C07K14/765;C07K19/00;C12Q1/02;G01N33/15 主分类号 A61K31/7004
代理机构 代理人
主权项
地址